Immuno-Oncology (IO) Platform
LIDE offers a comprehensive suite of immuno-oncology models and assays to accelerate the development of checkpoint inhibitors, bispecific antibodies, cell therapies, ADCs, oncolytic viruses, and other IO agents.
Syngeneic Models
Fully immunocompetent murine tumor models for rapid proof-of-concept and mechanism-of-action studies.
Learn more ›
Humanized In Vivo Models
Multiple formats including huPBMC-reconstituted, CD34+ HSC humanized, humanized syngeneic, and innate immune cell–involved systems (macrophage, dendritic cell).
Learn more ›
IO-FIVE®
A MiniPDX®-based rapid in vivo efficacy platform for IO drugs, using fresh patient tumors with matched immune components to deliver results in as little as 14 days.
Learn more ›
Ex Vivo & Co-Culture Assays
3D tumor–immune co-cultures, organoid assays, and functional immune profiling for high-throughput pre-validation and biomarker discovery.
Learn more ›
From early proof-of-concept through biomarker-driven clinical trial design, LIDE’s IO platforms provide speed, translational relevance, and a direct bridge to clinical reality.